Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) COO Jason Rickard sold 17,193 shares of the business’s stock in a transaction on Tuesday, November 23rd. The shares were sold at an average price of $11.58, for a total transaction of $199,094.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of IRWD opened at $11.58 on Thursday. Ironwood Pharmaceuticals, Inc. has a 52 week low of $8.78 and a 52 week high of $14.27. The firm has a market cap of $1.90 billion, a P/E ratio of 3.56 and a beta of 1.26. The firm’s 50-day simple moving average is $12.87 and its 200 day simple moving average is $12.63.
Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, November 4th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. The business had revenue of $103.75 million for the quarter, compared to analyst estimates of $105.27 million. Ironwood Pharmaceuticals had a net margin of 128.30% and a return on equity of 64.78%. The firm’s revenue for the quarter was up .3% on a year-over-year basis. During the same quarter last year, the business posted $0.23 EPS. Analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 1.29 earnings per share for the current year.
Several equities research analysts recently commented on IRWD shares. Morgan Stanley boosted their price objective on shares of Ironwood Pharmaceuticals from $13.00 to $14.00 and gave the company an “equal weight” rating in a research report on Tuesday, October 12th. TheStreet raised shares of Ironwood Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Thursday, November 4th. Finally, Zacks Investment Research raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating and set a $14.00 price objective on the stock in a research report on Monday, November 8th.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals, Inc is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation.
See Also: Google Finance Portfolio
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.